NETS

Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year

Retrieved on: 
onsdag, maj 29, 2024
Partnership, Patient, HFR, NRG, Energy, PALLAS, Prostate cancer, Cancer, NETS, Nuclear medicine, Medical imaging

PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for new irradiation services in Petten, Netherlands to produce non-carrier added lutetium-177 (Lu-177).

Key Points: 
  • PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for new irradiation services in Petten, Netherlands to produce non-carrier added lutetium-177 (Lu-177).
  • The extension of the partnership will further strengthen Curium’s plan to benefit more than 100,000 critically ill patients worldwide over the next five years.
  • The HFR reactor has been a pillar of the world’s patient access to molybdenum-99 (Mo-99) over the past 40+ years, and more recently for Lu-177.
  • Today’s announcement complements Curium’s existing global irradiation partnerships and ongoing dialogues with reactors elsewhere in the world.

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

Retrieved on: 
måndag, maj 20, 2024
MCI, ICI, Patient, CATX, SNMMI, MC1R, Therapy, Neoplasm, EANM, Safety, Society, Nivolumab, ICIS, Melanoma, Cancer, Nuclear medicine, FAP, Fibroblast, NETS, Glomus tumor, Annual general meeting, Pharmaceutical industry

“We are greatly encouraged by the progress of our clinical and preclinical programs," said Thijs Spoor, CEO of Perspective.

Key Points: 
  • “We are greatly encouraged by the progress of our clinical and preclinical programs," said Thijs Spoor, CEO of Perspective.
  • Updates on this trial as of March 7, 2024 were provided during the Company’s investor update on March 18, 2024, accessible on the events page of the Company’s website.
  • This study, in conjunction with the Phase 0 imaging study (NCT05111509), would inform the recommended Phase 2 dose of [212Pb]VMT-α-NET.
  • The most recent prior public update by the investigator was during the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in September 2023.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

Retrieved on: 
onsdag, maj 15, 2024
Molecular imaging, Mayo Clinic, Investment, PRRT, FDA, BMY, IND, EANM, Prostate, Ligand, Research, Antibody, PET, Bangladesh Technical Education Board, Stony Brook University, PSMA, Fortis Healthcare, Therapeutic index, Society, Neoplasm, Small business, CMC, Melanoma, Cohort, ATM, Bristol Myers Squibb, Business, CATX, Food, Disease, Safety, Cancer, Patient, Radiopharmaceutical, Adenocarcinoma, Nivolumab, Diagnosis, SNMMI, Therapy, Prostate cancer, LNTH, Nuclear medicine, Acquisition, NETS, Glomus tumor, MC1R, Pharmaceutical industry

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced first quarter financial results for the period ended March 31, 2024.

Key Points: 
  • SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced first quarter financial results for the period ended March 31, 2024.
  • “I am proud of the progress we are making with our clinical-stage proprietary radiopharmaceuticals,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • The Company was informed by the investigator that preliminary data readout is expected in the second half of 2024.
  • Updated results from Cohorts 1 and 2 of the Phase 1/2a study are expected in the second half of 2024.

IDTechEx Forecasts Durable, Engineered CO2 Removals Will Reach 630 Mt by 2044

Retrieved on: 
måndag, maj 13, 2024
Risk, BECCS, TRL, Climate, Soil, Investment, Ecosystem, Government, Atmosphere, Rise, Seaweed, Climate change, Growth, Research, Fertilisation, Biodiversity, Policy, Mineral, Carbon dioxide removal, Players, Biomass, NETS, CO2, CDR, Water, Market, Renewable energy

IDTechEx predicts that by 2044, the world's capacity for such durable, engineered CO2 removals will exceed 630 megatonnes per annum.

Key Points: 
  • IDTechEx predicts that by 2044, the world's capacity for such durable, engineered CO2 removals will exceed 630 megatonnes per annum.
  • Biomass with carbon removal and storage (BiCRS), which involves strategies that use biomass to remove CO2 from the atmosphere and store it underground or in long-lived products.
  • It includes approaches such as BECCS (bioenergy with carbon capture and storage), biochar, biomass burial, and bio-oil underground injection.
  • Instead, corporate buyers have increasingly turned towards highly durable, engineered carbon removal credits generated from approaches such as DACCS and BECCS.

IDTechEx Forecasts Durable, Engineered CO2 Removals Will Reach 630 Mt by 2044

Retrieved on: 
måndag, maj 13, 2024
Risk, BECCS, TRL, Climate, Soil, Investment, Ecosystem, Government, Atmosphere, Rise, Seaweed, Climate change, Growth, Research, Fertilisation, Biodiversity, Policy, Mineral, Carbon dioxide removal, Players, Biomass, NETS, CO2, CDR, Water, Market, Renewable energy

IDTechEx predicts that by 2044, the world's capacity for such durable, engineered CO2 removals will exceed 630 megatonnes per annum.

Key Points: 
  • IDTechEx predicts that by 2044, the world's capacity for such durable, engineered CO2 removals will exceed 630 megatonnes per annum.
  • Biomass with carbon removal and storage (BiCRS), which involves strategies that use biomass to remove CO2 from the atmosphere and store it underground or in long-lived products.
  • It includes approaches such as BECCS (bioenergy with carbon capture and storage), biochar, biomass burial, and bio-oil underground injection.
  • Instead, corporate buyers have increasingly turned towards highly durable, engineered carbon removal credits generated from approaches such as DACCS and BECCS.

VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update

Retrieved on: 
måndag, maj 13, 2024
Communication, Conference call, Eastern Time Zone, Conference, NETS

HENDERSON, Nev., May 13, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the first quarter of 2024.  Volition management will host a conference call tomorrow, May 14 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

Key Points: 
  • Tuesday, May 14 at 8:30 a.m. U.S. Eastern Time
    HENDERSON, Nev., May 13, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the first quarter of 2024.
  • Volition management will host a conference call tomorrow, May 14 at 8:30 a.m. U.S. Eastern Time to discuss these results.
  • Recorded approximately $170,000 in revenue in the first quarter of 2024, up 15% over the prior year.
  • The call will provide an update on important events which have taken place in the first quarter of 2024 and upcoming milestones.

Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update

Retrieved on: 
onsdag, maj 8, 2024
EEC, EDT, Investment, PDT, Aadi, Glomus tumor, Webcast, TSC2, Letrozole, LOS, AADI, TSC1, ID, Cancer, NETS, Perivascular epithelioid cell tumour, Telephone, Growth, Lung cancer, Pharmaceutical industry

LOS ANGELES, May 8, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Key Points: 
  • We look forward to providing the two-thirds interim analysis in the third quarter, and full results in early 2025.
  • The impacts to sales in the first quarter are well-understood events and we expect to return to sales growth in Q2."
  • The Aadi management team is hosting a conference call and webcast today at 8:30 am EDT (5:30 am PDT) to provide a corporate update and discuss results for the first quarter 2024.
  • Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com .

I Squared Portfolio Companies Transportation Equipment Network (“TEN”) and TIP Canada Combine Operations; Now the Second Largest Full-Service Trailer Lessor in North America

Retrieved on: 
måndag, april 15, 2024
Fleet Management, Finance, Asset Management, Automotive, Trucking, Other Automotive, Professional Services, Transport, TIP, Capital, NETS, Partner (business rank), CTL, Acquisition, Concept, Knowledge, Food delivery

Star Leasing), will acquire TIP Canada, the Canadian subsidiary of Europe-based TIP Group.

Key Points: 
  • Star Leasing), will acquire TIP Canada, the Canadian subsidiary of Europe-based TIP Group.
  • TIP Canada is the Canadian subsidiary of TIP Group, a leading player in the Canadian trailer leasing and rental market with a fleet of approximately 28,000 units.
  • TIP Canada also operates 12 workshop locations across Canada and 36 mobile service units providing coast-to-coast maintenance services to its own customers as well as third parties.
  • With the acquisition of TIP Canada, TEN will be North America’s second largest full-service trailer lessors with a combined fleet of over 83,000 trailers with locations across most major logistics hubs.

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Retrieved on: 
tisdag, april 23, 2024
FDA, Lutetium (177Lu) oxodotreotide, Brain, Cancer, Prostate, RLT, Hospital, Food, CHOP, Breast, B cell, Somatostatin, Disease, Incidence, Patient, Lung, National Cancer Institute, Diagnosis, Children's Hospital of Philadelphia, NETS, Ageing, Pharmaceutical industry

This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs.

Key Points: 
  • This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs.
  • "Lutathera is now the very first therapy approved specifically for children with GEP-NETs, offering new hope to young patients living with this rare cancer," said Tina Deignan, Therapeutic Area Head, Oncology US.
  • NETs are a type of cancer that originates in neuroendocrine cells throughout the body and are commonly considered slow-growing malignancies1.
  • In addition, the estimated radiation absorbed dose in pediatric patients was within established organ thresholds for external beam radiation and comparable to that in adults for the approved dose.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
torsdag, mars 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).